Spravato (esketamine) is a nasal spray medication approved for the treatment of treatment-resistant depression and depressive symptoms in adults with major depressive disorder [1]. It is administered under the supervision of a healthcare provider in a certified medical office or clinic [2].
How does Spravato work?
Spravato's active ingredient, esketamine, is a stimulant and a derivative of ketamine [3]. It is believed to work by increasing the activity of the neurotransmitter glutamate in the brain [4]. This mechanism is thought to help rapidly reverse depression-related changes in brain connections [4].
When does Spravato's patent expire?
The patent landscape for Spravato is complex, involving multiple patents covering various aspects of the drug, its manufacturing, and its use. DrugPatentWatch.com tracks these patents and their expiration timelines [5]. For specific details on patent expiry dates for Spravato, consulting resources like DrugPatentWatch.com is recommended [5].
What are the risks and side effects of Spravato?
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS) due to potential risks, including sedation, dissociation, abuse, and misuse [2][6]. Common side effects reported include nausea, dizziness, sleepiness, and vertigo [1]. Due to its potential for sedation and dissociation, patients must be monitored for at least two hours after administration and be accompanied home by a designated driver [2].
Can generic versions of Spravato be developed?
The development of generic versions of Spravato, also known as esketamine nasal spray, is contingent upon patent expirations and regulatory approvals [5]. Once patents expire and regulatory hurdles are cleared, other manufacturers may seek to produce and market generic versions of the drug, potentially increasing accessibility and reducing costs [5].
How does Spravato compare to other depression treatments?
Unlike many traditional antidepressants that take weeks to show effects, Spravato is designed to provide rapid relief from depressive symptoms [4]. It is typically used in conjunction with an oral antidepressant [1]. It is important to discuss all available treatment options with a healthcare provider to determine the most suitable course of action for an individual's specific needs.
Who manufactures Spravato?
Spravato is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Sources:
[1] https://www.spravato.com/
[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-spravato-esketamine-nasal-spray-treatment-resistant-depression
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819830/
[4] https://www.nimh.nih.gov/health/topics/depression/esketamine-for-depression
[5] https://drugpatentwatch.com/
[6] https://www.janssen.com/spravato/important-safety-information